今日神经病学最高分文献 - 2024-12-27

Hey, listeners! In a groundbreaking study featured in Neuro-oncology, the FDA-approved drug vorasidenib is making waves in the fight against IDH-mutant gliomas, the most common malignant brain tumors in young adults. This breakthrough provides a new hope with its ability to penetrate the brain and target mutant IDH1/2 proteins, potentially delaying the progression of these tumors and reducing reliance on aggressive therapies that impact quality of life. Tune in as we dive into the future of glioma treatment with vorasidenib and its promising clinical trials.